論文ID: JJID.2021.699
Coronavirus disease 2019 (COVID-19) expanded dramatically all over the world. Nafamostat mesylate inhibits the intracellular entry of novel severe acute respiratory syndrome coronavirus 2 and it has been thought as the therapeutic potential of treatment for patients with COVID-19. In the present study, patients with moderate COVID-19 who were admitted to our hospital were retrospectively analyzed. 31 patients received nafamostat mesylate monotherapy and 33 patients received conservative treatment. Nafamostat mesylate was initiated by continuous intravenous infusion for 4.5 days on average. Comparing with conservative treatment group, nafamostat mesylate did not improve the outcomes and laboratory data 5 days after admission. There were also no significant differences in the laboratory data 5 days after admission and outcomes in high-risk patients. Incidence of hyperkalemia was significantly higher in the nafamostat mesylate group, however, none of the patients required additional treatment for hyperkalemia. In conclusion, nafamostat mesylate monotherapy did not improve clinical outcomes in patients with moderate COVID-19. The therapeutic potential of the combination of nafamostat mesylate and other antiviral agents has not been examined in the present study, and further investigation is required. Because of high incidence of hyperkalemia, regular laboratory tests are required during the use of nafamostat mesylate.
